Can-Fite BioPharma Ltd. (NYSE: CANF) announced it has submitted the clinical trial protocol for its Phase II study of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE